In conclusion, we were able to demonstrate that the novel dual GLP‐1/GIP receptor agonist DA5‐CH which has a CPT modification to cross the BBB at an enhanced rate is capable of improving a range of key pathological features of PD in the MPTP mouse model. Here, GLP1R is linked to Parkinson disease.